Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Ocular Therapeutix Inc., 3 years.
Ocular Therapeutix Inc.
Director
Harrow Inc.
Director
Opus Genetics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Opus Genetics Inc. April 20, 202699.4%
-
Harrow Inc. June 18, 202597.0%
-
Opus Genetics Inc. April 30, 202587.7%
-
Harrow Inc. June 14, 202498.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 10, 2026 | Ocular Therapeutix Inc. | Grant or award | +14,000 | — | — |
| May 18, 2026 | Harrow Inc. | Open-market purchase | +1,000 | $31.07 | $31,070 |
| Apr 20, 2026 | Opus Genetics Inc. | Grant or award | +24,367 | — | — |
| Jan 1, 2026 | Opus Genetics Inc. | Grant or award | +23,643 | — | — |
| Jun 11, 2025 | Ocular Therapeutix Inc. | Grant or award | +14,000 | — | — |
| Apr 30, 2025 | Opus Genetics Inc. | Grant or award | +79,504 | — | — |
| Jul 24, 2024 | Ocular Therapeutix Inc. | Grant or award | +12,000 | — | — |
| Jul 10, 2023 | Ocular Therapeutix Inc. | Grant or award | +24,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.